BioSpace News Archive

I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the development of novel biologics, and ABL Bio, Inc. (Kosdaq:298380, hereafter “ABL”), a South Korean biotech specializing in bispecific antibody technology, jointly announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for initiating phase 1 trial for bispecific antibody TJ-CD4B/ABL111

Today, W. L. Gore & Associates, Inc. (Gore) announces the first use of the FDA approved GORE® EXCLUDER® Conformable AAA Endoprothesis with ACTIVE CONTROL System in cases outside of clinical trials

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for atogepant, an investigational orally administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant), for the preventive treatment of migraine in adults who meet criteria for episodic migraine

Dermata Therapeutics, Inc., a privately held biotechnology company, announced today that it has dosed its first patient in a Phase 1b trial of DMT310 for the treatment of mild-to-moderate psoriasis

Cold Chain Technologies announced that it is partnering with B Medical Systems, a Luxembourg-based manufacturer and global distributor of medical refrigeration and durable vaccine cold chain technology, to bring end-to-end thermal shipping and storage solutions to the life science market.

TMRW Life Sciences, Inc. (“TMRW” or “the Company”), creator of the world’s first and only automated cell management platform in the fast-growing in vitro fertilization (IVF) sector, named Tara Comonte Chief Executive Officer, effective May 10.

Around the globe, employees at Euromed’s seven administrative offices and three production facilities will reflect on the corporate contributions of phytomedicine researchers and chemical engineers that came before them and mark the golden anniversary of the firm.

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the publication of a peer-reviewed paper in eLife, a science journal, entitled,

Women and Infants Hospital in Providence, Rhode Island, has enrolled their first patient in the VESAIR Clinical Trial. The VESAIR Clinical Trial is being conducted in several distinguished clinics throughout the U.S. to test the Vesair Bladder Control Balloon procedure.

Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first-in-class antibody therapeutics, today announced the appointment of Dennis Giesing, Ph.D., to the role of Chief Development Officer (CDO). In this position,